Engineered CasX systems
CasX variants with modified domains and guide nucleic acids enhance gene editing efficiency by up to 81-fold, addressing the need for improved Class 2 CRISPR/Cas systems for therapeutic and research applications.
AU2020289591B2Pending Publication Date: 2026-07-23SCRIBE THERAPEUTICS INC
1 Cites 0 Cited by
Patent Information
- Application Number
- AU2020289591
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-05-27
- Filing Date
- 2020-06-05
- Publication Date
- 2026-07-23
- Estimated Expiration
- 2040-06-05
AI Technical Summary
Technical Problem
There is a need for additional Class 2 CRISPR/Cas systems that have been optimized and/or offer improvements over earlier generation systems for utilization in therapeutic, diagnostic, and research applications.
Method used
Development of CasX variants with modified domains such as NTSB, TSL, helical I, helical II, OBD, and RuvC domains, and guide nucleic acids with modified regions like extended stem loops and triplexes, which form complexes to bind target DNA and enhance editing efficiency.
Benefits of technology
The CasX variants exhibit improved gene editing capabilities, achieving up to 81-fold enhancement in editing efficiency compared to reference systems, and can edit both canonical and non-canonical PAMs effectively.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided herein are engineered CasX systems and components thereof, including variant CasX proteins and variant guide nucleic acids (gNAs). The variant CasX proteins and variant gNAs of the disclosure display at least one improved characteristic when compared to a reference CasX protein or reference gNA of the disclosure. In some instances, the variants have one or more improved CasX ribonucleoprotein complex functions. Also provided are methods of making and using said variants.
Need to check novelty before this filing date? Find Prior Art